Is Chemomab Therapeutics Ltd. (CMMB) a Buy, Sell, or Hold?
NASDAQ : CMMB
Chemomab Therapeutics Ltd.
$1.52 USD
$0 (0.0%)
- Volume
- 72.78K
- Average Volume
- 123.1K
- Market Capitalization
- $9.36M
- P/E Ratio
- -1.38
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $4.84
- Year Low
- $1.35
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.31
| Source | Headline |
|---|---|
|
Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript
Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript seekingalpha.com - 2026-07-08 12:32:42 |
|
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
Chemomab and Scipher announced a merger agreement to advance nebokitug into a Phase 2 precision medicine trial for the treatment of rheumatoid arthritis. globenewswire.com - 2026-07-08 07:35:00 |
|
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC Patients with Co-Existing IBD— —Company Continues to Advance Multiple Partnering Options for Nebokitug— TEL AVIV, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2026, and provided a corporate update. globenewswire.com - 2026-05-14 08:00:00 |
